tirzepatide patent expiry in india Semaglutide mid-March 2026 set to trigger entry of 50+ branded generics in India: Sheetal Sapale Semaglutide patent expiry in India

Regulatory status: FDA-approved for chronic weight management (2023) and obstructive sleep apnea in adults with obesity (2024, SURMOUNT-OSA)

[4] [10] It is important to distinguish injection site reactions from tirzepatide's systemic gastrointestinal side effects (nausea, vomiting, diarrhea), which are unrelated to injection location and represent the medication's most common adverse effects overall

Keeping a food diary can increase awareness of eating patterns and help identify triggers for overeating

Immune Response: Your body might see Semaglutide as a foreign substance

For now, peptide injections are best viewed as an experimental anti-aging tool , not a guaranteed solution

PMID: 38486057